CDC continues to investigate growing cases of lung illnesses for possible correlations to vape usage; a study suggests steroid inhaler use in patients with mild asthma may be ineffective; Oklahoma judge set to decide opioid lawsuit against Johnson & Johnson today.
Last Friday, the CDC identified 193 potential cases and 1 fatal case of severe lung illness linked to vaping in 22 states. Reuters reported that the CDC was investigating a “cluster” of lung illnesses believed to be caused by e-cigarette usage, but it has yet to find substantial evidence. Health agencies are continuing to examine potential cases of vaping-caused lung illnesses which have more than doubled over the past week. The president of the American Vaping Association, Gregory Conley, attributed growing lung illnesses toward the use of cannabis or other synthetic drugs contained in devices and denied that nicotine was the cause.
A new study published in the New England Journal of Medicine, examined the common use of steroid inhalers to prevent asthma attacks in patients. NPR reported that for many people with mild asthma, the target demographic for this treatment could be minimal as these steroid inhalers were found to not work any better than a placebo. In more than half of the cases in patients aged 12 and older, they exhibited just as well, or even better, on a placebo compared with steroid inhalers. Researchers stressed the need to reevaluate steroid inhaler use for patients with mild asthma as it may prove ineffective.
Oklahoma judge Thad Balkman is scheduled to rule today on the first state case to go to trial accusing Johnson & Johnson of responsibility for severe consequences occurring due to an addiction to painkillers, according to The Associated Press. Before the 6-week trial began in late May, Oklahoma reached a $270 million settlement from OxyContin manufacturer Purdue Pharma and an $85 million deal with Teva Pharmaceutical Industries Ltd. This case leads similar lawsuits by states, cities, counties, and Indian tribes that have sued drug companies for their role in the national opioid crisis.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More